Systemic Anti Cancer Therapy Protocols

These clinical protocols have been developed by local clinicians, with the support of the South West Clinical Network (SWCN). The information is provided as guidance only, and has no legal or official standing. The guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Availability of treatments may change, subject to NHS funding agreements. These protocols must be used in conjunction with local and national commissioning guidance.

The protocols are still being updated and more will be added to this website as they are completed. If you have any queries or suggestions, or would like to be involved in the development of these protocols please contact us

Dexamethasone, Rituximab and Cyclophosphamide

Lymphomas

Haematology

Chlorambucil

Lymphomas

Haematology

Cladribine

Lymphomas

Haematology

Bortezomib, Dexamethasone and Rituximab

Lymphomas

Haematology

Bendamustine 120 (NHL)

Lymphomas

Haematology

Abemaciclib

Metastatic

Oncology

Trastuzumab

Early and locally advanced disease

Oncology

Paclitaxel albumin (Abraxane)

Early and locally advanced disease

Oncology

Neoadjuvant, FEC-TPH

Early and locally advanced disease

Oncology

Adjuvant FEC-TPH

Early and locally advanced disease

Oncology

Fluorouracil, Epirubicin and Cyclophosphamide – Docetaxel (FEC-T)

Early and locally advanced disease

Oncology

Fluorouracil, Epirubicin (100) and Cyclophosphamide (FEC 100)

Early and locally advanced disease

Oncology

Search by filter

  • Haematology/Oncology

  • Location

  • Protocol Area